More on Blastic Plasmacytoid Dendritic-Cell Neoplasms
- 14 February 2019
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (7) , 695-697
Abstract
To the Editor: Agha and colleagues (Oct. 11 issue)1 described a patient with a blastic plasmacytoid dendritic-cell neoplasm who received bortezomib, simvastatin, and venetoclax. The study of BCL2 inhibition in acute myeloid leukemia2 and blastic plasmacytoid dendritic-cell neoplasm3,4 has been a long-standing focus for us. We previously reported our experience with venetoclax in the latter condition, demonstrating BCL2 dependence using BH3 profiling in primary tumor cells and patient-derived xenografts, and observing major responses to venetoclax monotherapy in two elderly patients with relapsed or refractory disease.3 On the basis of these findings, we have initiated a formal phase 1 trial of . . .Keywords
This publication has 6 references indexed in Scilit:
- Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell NeoplasmNew England Journal of Medicine, 2018
- Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasmLeukemia Research, 2018
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and BeyondCurrent Hematologic Malignancy Reports, 2017
- Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to VenetoclaxCancer Discovery, 2017
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery, 2016